查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年中枢神经系统药物市场预测：按疾病、药物类别、配销通路、年龄层和地区进行的全球分析
市场调查报告书
商品编码
1383398

2030 年中枢神经系统药物市场预测：按疾病、药物类别、配销通路、年龄层和地区进行的全球分析

Central Nervous System Therapeutics Market Forecasts to 2030 - Global Analysis By Disease, Drug Classes,Distribution Channel, Age Group and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球中枢神经系统治疗市场规模为 1,047 亿美元，预测期内年复合成长率为 8.2%，到 2030 年将达到 1,821.2 亿美元。

中枢神经系统 (CNS) 药物是用于治疗脑部和脊髓疾病的药物。中枢神经系统治疗药物是一个广泛的药物类别，包括许多不同类型的药物，每种药物都有特异性的作用机制。中枢神经系统药物用于治疗各种神经和精神疾病。常见的中枢神经系统药物包括用于治疗忧郁症和某些焦虑症的抗忧郁症药物、用于抑制癫痫发作的抗癫痫药物（这对于治疗癫痫、思觉失调症和躁郁症至关重要），以及用于治疗精神障碍的抗精神病药物。

世界卫生组织 (WHO) 报告称，全球有超过 5500 万人受到失智症影响，每年报告近 1000 万新病例。

创新药物输送系统的开发

治疗中枢神经系统疾病的新治疗方法的发展导致了创新药物传递系统的出现。这些尖端给药系统的诞生有望加速中枢神经系统市场的扩张。现代治疗方法和药物传输技术副作用极小或没有。此外，大众对神经退化性疾病和心理健康知识的了解不断增加，预计对中枢神经系统药物的需求将受到显着影响。

中枢神经系统药物高成本

CNS药物需要大量的研究和开发，这增加了CNS药物製造商的成本并提高了最终产品的价格。核准期限越长，投资风险越大。因此，中枢神经系统疾病药物供应商对其产品收取高价，以收回成本并保持盈利。然而，所有这些问题都对患者获得中枢神经系统药物产生负面影响，过高的定价甚至会阻碍中枢神经系统药物在消费潜力较低的地区的销售。这些因素是市场扩张的主要障碍。

民族意识

人们对心理健康和神经疾病的意识显着增强。这种认识的提高使得早期发现和治疗成为可能，因此，对中枢神经系统治疗的需求正在增加。此外，随着政府和医疗机构越来越认识到心理健康的重要性，医疗基础设施正在改善，医疗法规也已到位，以促进中枢神经系统药物的生产和分配。这导致了市场成长。

抗药性

中枢神经系统（CNS）治疗市场受到抗药性威胁的困扰。这种症候群常见于癫痫等疾病，患者逐渐对先前有效的药物变得不耐受。这不仅降低了治疗效果，还需要开发新的治疗方法。抗药性使得治疗中枢神经系统疾病变得更加困难，因此研究人员必须不断想出新的解决方案来解决这个问题。抗药性患者可能很难找到有效的药物，对疾病的控制能力较差，并且可能需要更强化的治疗。这些因素都阻碍了市场需求。

COVID-19 的影响

中枢神经系统治疗市场受到了 COVID-19大流行的严重影响。受疫情影响，接受中枢神经系统疾病治疗的人数甚至核准治疗中枢神经系统的新药数量都减少了。此外，大流行扰乱了正在进行的中枢神经系统疾病的治疗研究和临床试验。由于患者招募限制、医疗设施使用受限以及优先考虑 COVID-19 研究，一些临床试验不得不取消或搁置。结果，新的中枢神经系统药物的开发和监管核准被推迟。

预计抗忧郁症市场在预测期内将是最大的市场。

抗忧郁症市场估计占最大份额。其中包括增加对忧郁症和焦虑等精神健康疾病的认识和识别，改善获得精神健康服务的机会，以及抗忧郁症在治疗各种中枢神经系统疾病中的效用和有效性。这是精神健康疾病率上升的一个因素失调。抗忧郁症的开发在製药部门取得了重大进展。创新类型的抗忧郁症，例如选择性选择性血清素再回收抑制剂（SSRI）、血清素和去甲肾上腺素再回收抑制剂（SNRI）以及非典型抗忧郁症，与老一代药物相比具有更高的疗效和耐受性。

预计儿童产业在预测期内将经历最高的年复合成长率。

预计儿童细分市场在预测期内将出现良好成长。神经系统治疗市场的儿童部门专门为患有神经系统疾病和失调的儿童提供专门的治疗解决方案和方案。这包括遗传性疾病、癫痫、脑性麻痹麻痹、过动症、泛自闭症障碍等。此类别重点在于儿童用药物製剂、儿童医疗设备以及适龄诊断设备的生产和销售。开拓早期疗育意识、儿童神经系统疾病的发生率、儿童神经学研究和治疗方法发展都是推动市场的因素。

比最大的地区

由于製药业的技术进步有助于开发新药、产品上市增加、中枢神经系统疾病负担增加以及美国。获得。此外，神经系统疾病盛行率的上升可能会增加对提供尖端治疗方法方法的研究计划的资金和支持，从而加速市场扩张。

复合年复合成长率最高的地区：

预计亚太地区在预测期内将实现盈利成长。主要的市场驱动因素是政府在加强医疗基础设施方面的投资不断增加，以及大量患者的医疗需求未被满足。该非营利组织透过提高人们对心理健康和中枢神经系统药物的认识，同时为中枢神经系统疾病提供免费治疗，做出了巨大的贡献。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球中枢神经系统治疗市场：依疾病分类

  • 神经血管疾病
  • 精神健康
    • 焦虑症
    • 癫痫
    • 情绪障碍
    • 精神障碍
  • 退化性疾病
    • 帕金森氏症
    • 阿兹海默症
    • 亨丁顿舞蹈症
    • 多发性硬化症
    • 肌萎缩侧索硬化症
  • 中枢神经系统创伤
  • 中枢神经系统癌症
  • 感染疾病
  • 其他疾病

第6章全球中枢神经系统治疗市场：依药物类别

  • 抗忧郁症
  • 止痛药
  • 麻醉剂
  • 抗帕金森氏症药物
  • 抗癫痫药
  • 脱羧酶抑制剂
  • 多巴胺促效剂
  • 免疫调节剂
  • 其他药物类别

第7章全球中枢神经系统治疗市场：按配销通路

  • 零售药房
  • 医院药房
  • 网路药房

第8章全球中枢神经系统治疗市场：依年龄组别

  • 儿童
  • 老年人
  • 成人

第9章全球中枢神经系统治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Biogen
  • Astra Zeneca
  • Eli Lilly and Company
  • Merck & Co.
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Hand Pharma, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Shire PLC
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
Product Code: SMRC24248

According to Stratistics MRC, the Global Central Nervous System Therapeutics Market is accounted for $104.7 billion in 2023 and is expected to reach $182.12 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Central Nervous System (CNS) therapeutics are drugs that are used to treat diseases of the brain and spinal cord. They are a broad class of drugs that include many different types, each with its own specific mechanism of action. CNS therapeutics is used to treat a wide range of neurological and psychiatric conditions. Some common CNS therapeutics include antidepressants, which are used to treat depression and certain anxiety disorders, anti-epileptics, which are used to control seizures and are essential in the treatment of epilepsy, antipsychotics, which are used to manage psychotic disorders like schizophrenia and bipolar disorders, etc.

According to the World Health Organization (WHO) report, more than 55 million people have dementia worldwide, and nearly 10 million new cases are reported yearly.

Market Dynamics:

Driver:

Development of innovative drug delivery systems

Innovative drug delivery systems have emerged as a result of the development of new therapies for the treatment of illnesses of the central nervous system. The creation of these cutting-edge drug delivery systems is anticipated to accelerate the expansion of the market for the central nervous system. The adverse effects of modern treatments and medication delivery technologies are minimal or nonexistent. Additionally, the demand for therapies for the central nervous system is anticipated to be significantly impacted by the population's growing knowledge of neurodegenerative diseases and mental health.

Restraint:

High costs of CNS drugs

CNS medications require considerable research and development, which is expensive for CNS drug makers and raises the final product's cost. Longer approval durations further raise the risk of investing; thus, CNS drug suppliers price their goods high to recover their expenses and maintain profitability. However, these issues all have a negative impact on patients who acquire these CNS medications and excessive prices even prevent the sale of CNS medications in areas with little spending potential. These elements are significant barriers to market expansion.

Opportunity:

Public awareness

Public awareness about mental health and neurological disorders has grown significantly. The need for CNS medications has increased as a result of the early identification and treatment made possible by this enhanced awareness. Additionally, governments and healthcare institutions are becoming more aware of the significance of mental health, which has improved healthcare infrastructure and led to better healthcare regulations that promote the creation and distribution of CNS medications. Therefore, it leads to market growth.

Threat:

Drug resistance

The therapeutic market for the central nervous system (CNS) is concerned by the threat of drug resistance. Patients gradually become less receptive to previously effective drugs in this syndrome, which is frequently seen in disorders like epilepsy. It not only lowers therapy effectiveness but also forces the creation of new treatments. Drug resistance makes treating CNS illnesses more difficult, and researchers must constantly come up with new solutions to this problem. Patients who have resistance can have trouble locating effective medications, which could lead to insufficient illness control and the requirement for more intrusive measures. These factors hinder market demand.

COVID-19 Impact

The market for treatments for the central nervous system was significantly impacted by the COVID-19 pandemic. Even the number of people receiving treatment for CNS illnesses and the number of new CNS drugs approved has decreased as a result of the epidemic. Additionally, the pandemic interfered with ongoing CNS therapeutic research and clinical trials. Due to limitations on patient recruitment, restricted access to medical facilities, and the priority given to COVID-19 research, several trials had to be stopped or put on hold. New CNS medicines' development and regulatory approval were subsequently delayed as a result.

The antidepressant segment is expected to be the largest during the forecast period.

The antidepressant segment is estimated to hold the largest share. Increased knowledge and identification of mental health conditions like depression and anxiety, better access to mental health services, and the usefulness and efficacy of antidepressants in treating a variety of CNS illnesses are all contributing factors to the rising prevalence of mental health problems like these. Antidepressant medication development has advanced significantly in the pharmaceutical sector. Innovative types of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-nor epinephrine reuptake inhibitors (SNRIs), and atypical antidepressants, offer higher efficacy and tolerability profiles as compared to earlier generations of medications.

The paediatric segment is expected to have the highest CAGR during the forecast period.

The paediatric segment is anticipated to have lucrative growth during the forecast period. The Paediatric segment of the Nervous System Therapeutics Market is dedicated to therapeutic solutions and regimens created especially for children with neurological illnesses and disorders. These include hereditary illnesses, epilepsy, cerebral palsy, ADHD, and autism spectrum disorders. The category focuses on the creation and distribution of paediatric medication formulations, kid-friendly medical gadgets, and age-appropriate diagnostic equipment. Growing awareness of early intervention, the frequency of neurological illnesses in children, and developments in paediatric neurology research and therapies are all driving factors in the market.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to the growth of technology in the pharmaceutical sector that helps in new drug developments, increasing product launches, the rising burden of central nervous system diseases, and the rising level of research and developments in the countries like the United States and Canada. Additionally, the prevalence of neurological disorders is rising, which increases funding and support for research initiatives that provide cutting-edge therapies and could accelerate the market's expansion.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. The major market drivers are the growing government investments in enhancing the healthcare infrastructure and the prevalence of numerous patients with unmet medical needs. The non-profit organisations are doing an outstanding job of raising awareness about mental health and CNS therapeutics while also offering free treatments for CNS illnesses.

Key players in the market

Some of the key players in the Central Nervous System Therapeutics Market include: Biogen, Astra Zeneca, Eli Lilly and Company, Merck & Co., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Hand Pharma, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shire PLC, GlaxoSmithKline PLC and Pfizer, Inc.

Key Developments:

In February 2023, Sage Therapeutics, Inc. and Biogen Inc received acceptance from the United States FDA for a New Drug Application (NDA) application for zuranolone in the treatment of the major depressive disorder (MDD) and postpartum depression (PPD).

In January 2023, Biogen Inc. received Accelerated Approval from United States FDA for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (AB) for the treatment of Alzheimer's disease (AD).

Diseases Covered:

  • Neurovascular Diseases
  • Mental Health
  • Degenerative Disorders
  • CNS Trauma
  • CNS Cancer
  • Infectious Diseases
  • Other Diseases

Drug Classes Covered:

  • Antidepressant
  • Analgesics
  • Anesthetics
  • Anti-Parkinson Drugs
  • Anti-Epileptics
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Immunomodulatory Drug
  • Other Drug Classes

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital-Based Pharmacies
  • Online Pharmacy

Age Groups Covered:

  • Pediatric
  • Geriatric
  • Adults

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Central Nervous System Therapeutics Market, By Disease

  • 5.1 Introduction
  • 5.2 Neurovascular Diseases
  • 5.3 Mental Health
    • 5.3.1 Anxiety Disorders
    • 5.3.2 Epilepsy
    • 5.3.3 Mood Disorders
    • 5.3.4 Psychotic Disorders
  • 5.4 Degenerative Disorders
    • 5.4.1 Parkinson's Disease
    • 5.4.2 Alzheimer's Disease
    • 5.4.3 Huntington's Disease
    • 5.4.4 Multiple Sclerosis
    • 5.4.5 Amyotrophic Lateral Sclerosis
  • 5.5 CNS Trauma
  • 5.6 CNS Cancer
  • 5.7 Infectious Diseases
  • 5.8 Other Diseases

6 Global Central Nervous System Therapeutics Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antidepressant
  • 6.3 Analgesics
  • 6.4 Anesthetics
  • 6.5 Anti-Parkinson Drugs
  • 6.6 Anti-Epileptics
  • 6.7 Decarboxylase Inhibitors
  • 6.8 Dopamine Agonists
  • 6.9 Immunomodulatory Drug
  • 6.10 Other Drug Classes

7 Global Central Nervous System Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacy
  • 7.3 Hospital-Based Pharmacies
  • 7.4 Online Pharmacy

8 Global Central Nervous System Therapeutics Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric
  • 8.3 Geriatric
  • 8.4 Adults

9 Global Central Nervous System Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Biogen
  • 11.2 Astra Zeneca
  • 11.3 Eli Lilly and Company
  • 11.4 Merck & Co.
  • 11.5 Johnson & Johnson Services, Inc.
  • 11.6 Otsuka Pharmaceutical Co., Ltd.
  • 11.7 Hand Pharma, Inc.
  • 11.8 Novartis AG
  • 11.9 Takeda Pharmaceutical Company Limited
  • 11.10 Teva Pharmaceutical Industries Ltd.
  • 11.11 Shire PLC
  • 11.12 GlaxoSmithKline PLC
  • 11.13 Pfizer, Inc.

List of Tables

  • Table 1 Global Central Nervous System Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Central Nervous System Therapeutics Market Outlook, By Disease (2021-2030) ($MN)
  • Table 3 Global Central Nervous System Therapeutics Market Outlook, By Neurovascular Diseases (2021-2030) ($MN)
  • Table 4 Global Central Nervous System Therapeutics Market Outlook, By Mental Health (2021-2030) ($MN)
  • Table 5 Global Central Nervous System Therapeutics Market Outlook, By Anxiety Disorders (2021-2030) ($MN)
  • Table 6 Global Central Nervous System Therapeutics Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 7 Global Central Nervous System Therapeutics Market Outlook, By Mood Disorders (2021-2030) ($MN)
  • Table 8 Global Central Nervous System Therapeutics Market Outlook, By Psychotic Disorders (2021-2030) ($MN)
  • Table 9 Global Central Nervous System Therapeutics Market Outlook, By Degenerative Disorders (2021-2030) ($MN)
  • Table 10 Global Central Nervous System Therapeutics Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 11 Global Central Nervous System Therapeutics Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 12 Global Central Nervous System Therapeutics Market Outlook, By Huntington's Disease (2021-2030) ($MN)
  • Table 13 Global Central Nervous System Therapeutics Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 14 Global Central Nervous System Therapeutics Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 15 Global Central Nervous System Therapeutics Market Outlook, By CNS Trauma (2021-2030) ($MN)
  • Table 16 Global Central Nervous System Therapeutics Market Outlook, By CNS Cancer (2021-2030) ($MN)
  • Table 17 Global Central Nervous System Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 18 Global Central Nervous System Therapeutics Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 19 Global Central Nervous System Therapeutics Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 20 Global Central Nervous System Therapeutics Market Outlook, By Antidepressant (2021-2030) ($MN)
  • Table 21 Global Central Nervous System Therapeutics Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 22 Global Central Nervous System Therapeutics Market Outlook, By Anesthetics (2021-2030) ($MN)
  • Table 23 Global Central Nervous System Therapeutics Market Outlook, By Anti-Parkinson Drugs (2021-2030) ($MN)
  • Table 24 Global Central Nervous System Therapeutics Market Outlook, By Anti-Epileptics (2021-2030) ($MN)
  • Table 25 Global Central Nervous System Therapeutics Market Outlook, By Decarboxylase Inhibitors (2021-2030) ($MN)
  • Table 26 Global Central Nervous System Therapeutics Market Outlook, By Dopamine Agonists (2021-2030) ($MN)
  • Table 27 Global Central Nervous System Therapeutics Market Outlook, By Immunomodulatory Drug (2021-2030) ($MN)
  • Table 28 Global Central Nervous System Therapeutics Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 29 Global Central Nervous System Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 Global Central Nervous System Therapeutics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 31 Global Central Nervous System Therapeutics Market Outlook, By Hospital-Based Pharmacies (2021-2030) ($MN)
  • Table 32 Global Central Nervous System Therapeutics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 33 Global Central Nervous System Therapeutics Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 34 Global Central Nervous System Therapeutics Market Outlook, By Pediatric (2021-2030) ($MN)
  • Table 35 Global Central Nervous System Therapeutics Market Outlook, By Geriatric (2021-2030) ($MN)
  • Table 36 Global Central Nervous System Therapeutics Market Outlook, By Adults (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.